Author:
Villano J.L.,Mauer A.M.,Vokes E.E.
Reference5 articles.
1. Phase I study of dose-dense alternating doublets in advanced non-small-cell lung cancer;Vokes;Clin Lung Cancer,2002
2. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer;Barker;Bioorg Med Chem Lett,2001
3. Oral administration of the specific EGFR tyrosine kinase inhibitor, ZD1839 (Iressa), is active against EGFR-overexpressing intracranial tumors;Heimberger;Proceedings of the 11th NCI•EORTC•AACR Symposium on New Drugs in Cancer Therapy, Amsterdam. Clin Cancer Res,1993
4. Epidermal growth factor-related peptides and their receptors in human malignancies;Salomon;Crit Rev Oncol Hematol,1995
5. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial;Ranson;J Clin Oncol,2002
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献